clinical trial · NCT07591285
A Study of SYS6051 in Subjects With Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.·phase1·not yet recruiting·n = 114
Advanced Solid TumorsSYS6051
brief summary
This is a multicenter, open-label, dose-escalation and backfill, and cohort-expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor efficacy of SYS6051 in participants with advanced solid tumors.
started
May 12, 2026
primary completion
May 31, 2028
completion
Jun 30, 2028
last updated
May 15, 2026
official title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SYS6051 in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol